NKTR - Company ID 0000906709
The table below shows NEKTAR THERAPEUTICS's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $10.86M | $11.79M | $11.18M | $10.46M | $24.12M | $23.49M |
| Cost of revenue | - | $0.00 | $0.00 | $0.00 | $4.43M | $9.74M |
| Gross profit | - | - | - | - | - | - |
| R&D | $35.68M | $27.25M | $29.89M | $30.48M | $35.03M | $29.72M |
NEKTAR THERAPEUTICS reported annual revenue of $55.23M for fiscal year 2025. That is down 43.9% from $98.43M in fiscal 2024. Over the 10 fiscal years shown, annual revenue declined from $165.44M (FY 2016) to $55.23M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $13.44M |
| $16.07M |
| $17.07M |
| $24.35M |
| $18.96M |
| $20.51M |
| Operating income | -$39.05M | -$31.67M | -$36.23M | -$44.53M | -$34.34M | -$49.77M |
| Income tax | $64.00K | -$33.00K | -$188.00K | $52.00K | $9.00K | $46.00K |
| Net income | -$44.90M | -$35.52M | -$41.59M | -$50.88M | -$37.06M | -$52.36M |
| EPS (diluted) | -$1.82 | -$1.87 | -$2.95 | -$3.62 | -$2.66 | -$3.76 |